FDA's September MedSun newsletter includes one submitted report in which an incorrect hand-dominance entry changed a retrospective lymphedema assessment.
Source date
September 2026 MedSun newsletter; checked September 15, 2026
Who should care
Lymphedema programs evaluating data-entry and result-review controls
Next action
Test when hand dominance is collected, which fields affect calculations, how corrections are logged, and who verifies inputs before interpreting a result.
Trace the contained component before releasing an epidural kit
Verified regulatory record
FDA's September 10 communication classifies the Medical Action Industries correction as a Class I recall. It says this action corrects certain devices rather than removing the kits from use or sale.
The affected table names item numbers 82465, 59553, and 83945B, with specific lot numbers and three UDIs. FDA directs users to quarantine affected kits until labels are applied, then remove and discard the Sodium Chloride 0.9% USP 10 mL flush ampules before use. The other kit components may be used.
FDA says the kits may contain sodium chloride ampules made by Huons and recalled by Spectra Medical Devices. The page describes possible contamination hazards and says Medical Action Industries had reported no serious injuries or deaths as of July 23.
Editorial interpretation
Inventory control needs to reach the component level. Record the kit item number, lot, UDI, quarantine status, label placement, ampule removal, disposal, and the person who released the remaining components.
Limit
The communication does not say every epidural kit or every component is affected. Its injury statement is a dated company-report status, not an incidence rate or guarantee. Use the live table for the exact item and lot.
Venti-Trach starts with series-level purchasing records
Verified regulatory record
FDA's 510(k) page identifies K253063 as Venti-Trach Tracheostomy Tube series 570, 571, 580, and 581 from Vitaltec Corporation.
The special 510(k) was received September 22, 2025 and found substantially equivalent on September 11, 2026. FDA lists regulation 21 CFR 868.5800, product code BTO, and the anesthesiology panel.
The page says the submission was not reviewed by a third party, is not a combination product, and has no authorized predetermined change control plan. The reviewed page does not link a public summary.
Editorial interpretation
A supply review should name the exact series, sizes, connectors, accessories, labeling, compatible equipment, training, lot traceability, shelf life, reorder terms, and substitution controls.
Limit
Substantial equivalence is clearance, not premarket approval or proof of clinical superiority, supply reliability, service quality, or fit for a specific patient. The record alone does not support detailed configuration or performance claims.
Move calculation-sensitive inputs to a verified checkpoint
FDA-hosted voluntary report
FDA's September MedSun newsletter says highlighted reports are a cross section of device-related events submitted by MedSun representatives. The reports appear as submitted and may be summarized or edited for clarity.
One report concerns ImpediMed's SOZOapp. It says staff entered right-hand dominance before a patient arrived because the actual value was not yet known. The patient was left-handed, and the entry was not changed before the assessment.
The report says a later correction changed the retrospective lymphedema assessment. The submitter recommended moving hand dominance and other calculation-sensitive questions closer to the assessment so staff can verify them with the patient.
Editorial interpretation
In a demo or acceptance test, enter an intentionally wrong calculation-sensitive field, correct it, and verify the result, audit trail, alerting, user permissions, and downstream record update.
Limit
This is one voluntary MedSun report, not an FDA finding of causality, a recall, a measured error rate, or proof of performance across installations. The public report does not provide the full investigation, denominator, or software version.
The Morpheus8 RF Pro ask remains visible for a fifth weekly check
Dated market observation
Sample: 1Asking price, USDTexas, United StatesSeller-described used, excellent
DOTmed listing 4706842 remained visible and marked in stock on September 15 at a $27,999 USD asking price. It describes one used/excellent 2022 InMode Morpheus8 RF Pro in Texas with face and body attachments and a seller-stated 30-day warranty.
Configuration: Seller-described 2022 Morpheus8 RF Pro with face and body attachments.
Editorial interpretation
The repeated check shows listing visibility, not price discovery or demand. Verify the exact platform and serial number, attachments, title, service history, software and consumable eligibility, transfer fees, inspection window, shipping, training, return terms, and warranty provider.
Limit
Device Pulse did not inspect the unit, contact the seller, validate the configuration or warranty, or observe a transaction. One visible ask is not a completed sale, range, median, or market price. Continued visibility does not prove buyer interest or rejection.
For every procedural kit, require a component list that maps item number, lot, UDI, manufacturer, recall status, quarantine decision, replacement, and final release.
A kit can remain usable after one contained component is removed. The release record should prove that staff found the right kit and removed the right item.
Research shortcut
Browse rehabilitation and lymphedema research paths
Use the Buyer’s Guide and rehabilitation categories to map device identity, software inputs, training, service, and evidence questions without passing through a signup gate.
One question each week about what independent practices are evaluating, replacing, or rejecting, with results held back until the sample can support a useful benchmark.
Zero-data poll state
One question
Which equipment category is most likely to enter your practice's evaluation list in the next 12 months?
No response is being collected on this page. The choices open current Device Pulse research. The participation control records interest in answering, not an answer or survey response.
Which data-entry controls and audit records belong in a software-assisted assessment review?
Limit This is an editorial research prompt, not reported purchase intent.
What practices paid
Not available
No practice-paid benchmark is available. A future result needs dated observations, the usable sample, configuration, condition, geography, currency, and price type.
Market development
Launch, recall, or market development
This issue's epidural-kit correction and Venti-Trach clearance are source-backed developments. The peer-intelligence module does not change their evidence class or limitations.
Buyer question
Ask before the next quote
Which input can change the result, and who verifies it before anyone acts?
Send this page to the person who reviews clinical evidence, the person who owns the capital budget, and the person who will manage service calls. Keep the direct source links with the interpretation. A forwarded summary without the identifier, date, configuration, or limitation loses the part that makes it useful.
If a colleague owns an affected unit or has an active quote, ask them to open the live record. FDA recall status and manufacturer instructions can change after an archive date. A company release can be replaced by a later filing. A marketplace listing can change or disappear without proving that a unit sold.
Use the public archive for prior issues, the Buyer’s Guide for device research, the research methodology for evidence rules, and the visible correction section when a material record changes. Signup is optional. This web edition was not sent by email.
Frequently Asked Questions
Was this briefing sent to subscribers?
No. This is a public web issue. No subscriber list was accessed or contacted.
Must every affected epidural kit be discarded?
FDA says to quarantine affected kits, apply the warning label, remove and discard the named sodium chloride ampule, and then use the remaining components. Check the live item and lot table.
Is K253063 an FDA approval?
No. FDA records a special 510(k) substantial-equivalence decision. That is clearance, not premarket approval or proof of superiority.
Does the SOZOapp report establish an error rate?
No. It is one voluntary MedSun report without a denominator, full investigation, or software version.
Is the DOTmed price a completed transaction?
No. It is one seller-controlled asking price for one visible listing. No completed sale was observed.
Where are the reader poll results?
There are none. Results stay unpublished until real responses meet the documented minimum sample and methodology requirements.
Get the Device Quote Review Kit
Open the printable buyer checklist now, then get the planned Tuesday brief with price, FDA, safety, evidence, and manufacturer signals.
Free kit available immediately. Planned Tuesday brief. Unsubscribe anytime. Privacy.